Renal Week 2010 - Renal and Urology News

If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Follow our archived coverage from Renal Week - the American Society of Nephrology's annual meeting and scientific exposition - in Denver. Our coverage included four blogs updated daily with multiple stories.

Sections: Anemia | Hyperphosphatemia
Secondary Hyperparathyroidism | General News
More: Videos | Photos

Everolimus May Reduce CMV Risk

John Schieszer February 24, 2011

DENVER—Use of everolimus (EVR) rather than mycophenolic acid (MPA) in renal transplant recipients may significant decrease the risk for cytomegalovirus events, according to a study.

Artery Size and Diabetes Predict AVF Patency

John Schieszer February 24, 2011

DENVER—Artery size is the only predictor of both primary and secondary patency in arteriovenous fistula (AVF) placement in hemodialysis (HD) patients, researchers reported at Renal Week 2010. The presence of diabetes predicted primary patency only.

CAB Surgery May Be Superior to Stents Long Term

John Schieszer February 24, 2011

DENVER—Drug-eluting stents (DES) provide the best short-term survival for dialysis patients who require coronary revascularization, but coronary artery bypass (CAB) surgery may offer better long-term survival, researchers reported at the 2010 Renal Week conference.

Novel Binder Lowers Phosphorus, LDL Cholesterol

Jody A. Charnow January 24, 2011

An investigational calcium-free phosphate binder called colestilan is safe and effective for controlling phosphorus in dialysis patients, and it has no impact on calcium levels, researchers reported.

Lipid Lowering Reduces Cardiovascular Risk in CKD Patients

John Schieszer January 24, 2011

Cholesterol-lowering treatment with a combination of ezetimibe and simvastatin significantly decreases the likelihood of major atherosclerotic events in patients with chronic kidney disease (CKD), according to the findings of the five-year Study of Heart and Renal Protection (SHARP) trial.

Investigational Drug May Reverse CKD

Jody A. Charnow December 21, 2010

DENVER—Recent trial data suggest that an investigational agent called bardoxolone methyl may improve renal function in type 2 diabetics with moderate to severe chronic kidney disease (CKD).

Lowering Cholesterol Reduces CV Event Risk in CKD Patients

John Schieszer December 08, 2010

DENVER—Cholesterol-lowering treatment with a combination of ezetimibe and simvastatin significantly decreases the likelihood of major atherosclerotic events in patients with chronic kidney disease (CKD), according to the findings of the five-year Study of Heart and Renal Protection (SHARP) trial.

Worsening Kidney Disease in Blacks Linked to Gene Variant

John Schieszer November 20, 2010

A common gene variant appears to be associated with a sharply increased risk of progressive kidney disease in African Americans (AAs) with hypertensive nephrosclerosis, according to a study presented at Renal Week 2010 in Denver.

FGF-23 Linked to Cinacalcet Use

John Schieszer November 20, 2010

Fibroblast growth factor 23 (FGF-23) is positively associated with cinacalcet use, calcium, and phosphorus in hemodialysis (HD) patients, according to a study presented at Renal Week 2010 in Denver.

Phosphate, FGF-23 Rise in PD Patients as Residual Renal Function Declines

Jody A. Charnow November 20, 2010

Serum phosphate and fibroblast growth factor 23 (FGF-23) levels increase in incident peritoneal dialysis (PD) patients increase as residual renal function declines, according to researchers who presented their findings at Renal Week 2010 in Denver.

H1N1 Vaccine May Not Protect Most Kidney Transplant Recipients

John Schieszer November 20, 2010

Most renal transplant recipients may not benefit from being vaccinated against the H1N1 influenza virus, according to a new German study presented at Renal Week 2010 in Denver.

Target Higher Hb May Be Renoprotective in Tx Patients

Jody A. Charnow November 20, 2010

Researchers at Renal Week 2010 in Denver have reported on what they believe is the first prospective, randomized study to show that targeting a serum hemoglobin (Hb) level of 13 g/dL or higher has a renoprotective effect in kidney transplant patients.

SHPT in Dialysis Patients Associated with Greater Mortality, Morbidity

John Schieszer November 20, 2010

New data presented at Renal Week 2010 in Denver confirm the high morbidity and mortality associated with secondary hyperparathyroidism (SHPT) in dialysis patients, emphasizing the need for early referral as well as other therapeutic interventions.

Oral Paricalcitol May Have Similar Efficacy to Oral Calcitriol

John Schieszer November 20, 2010

Oral paricalcitol (OP) appears to have similar efficacy and safety compared with oral calcitriol (OC) in dialysis patients with secondary hyperparathyroidism (SHPT), according to results from a randomized, controlled trial presented at Renal Week 2010 in Denver.

High Phosphocalcic Product May Rule Out Transplants

Jody A. Charnow November 20, 2010

A high phosphocalcic product significantly increases the risk of non- eligibility for a kidney transplant among adults with end-stage renal disease (ESRD), Canadian researchers concluded in a study presented at Renal Week 2010 in Denver.

Pomegranate Juice May Benefit Dialysis Patients

John Schieszer November 20, 2010

Pomegranate juice may ward off a number of complications in dialysis patients.

Cinacalcet for SHPT Safe, Effective in Renal Transplant Recipients

John Schieszer November 20, 2010

Cinacalcet is a safe and effective option for treating hypocalcemia and secondary hyperparathyroidism (SHPT) in renal transplant recipients, according to a new German study presented at Renal Week 2010 in Denver.

High Phosphorus May Predict Faster CKD Progression

Jody A. Charnow November 20, 2010

High baseline serum phosphorus levels in CKD patients may predict an increased likelihood of renal disease progression and death, according to Italian investigators, who presented their findings at Renal Week 2010 in Denver.

Anemia Frequently Untreated in Non-Dialysis CKD Patients

Jody A. Charnow November 20, 2010

A significant proportion of patients with CKD but not on dialysis (CKD-NOD) with new-onset moderately severe anemia do not receive treatment with iron or erythropoiesis-stimulating agents (ESAs), suggest study findings presented at Renal Week 2010 in Denver.

ARBs May Affect Response to Erythropoiesis-Stimulating Agents

Jody A. Charnow November 20, 2010

Angiotensin receptor blocker (ARB) treatment may affect response to erythropoiesis-stimulating agents (ESAs) in hemodialysis (HD) patients by disturbing iron homeostasis, Japanese researchers reported at Renal Week 2010 in Denver.